Pre-treatment pan-immune-inflammation value as a prognostic marker of pazopanib in soft tissue sarcoma

被引:0
|
作者
Wu, Cheng-Han [1 ,3 ]
Lai, Cheng-Lun [1 ]
Hsu, Yong-Chen [4 ]
Hsu, Chiann-Yi [5 ]
Wang, Yu-Chao [3 ]
Lin, Hsin-Chen [1 ,2 ]
机构
[1] Taichung Vet Gen Hosp, Dept Oncol, Div Med Oncol, Taichung 407219, Taiwan
[2] Natl Chung Hsing Univ, Coll Med, Dept Postbaccalaureate Med, Taichung 402202, Taiwan
[3] Natl Yang Ming Chiao Tung Univ, Inst Biomed Informat, Taipei, Taiwan
[4] Taichung Vet Gen Hosp, Dept Pathol, Taichung, Taiwan
[5] Taichung Vet Gen Hosp, Biostat Task Force, Taichung, Taiwan
关键词
pan-immune-inflammation value; pazopanib; sarcoma; RATIO;
D O I
10.1177/17588359241292255
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Increasingly, more evidence has shown that inflammation stress and the tumor microenvironment pose a negative effect on targeted therapy. The neutrophil-to-lymphocyte ratio is considered to be a surrogate biomarker of inflammation and can predict pazopanib treatment effect in non-adipocytic soft-tissue sarcoma (STS). The role of the pan-immune-inflammation value (PIV) in STS is still yet to be determined. Objectives: We sought whether the pre-treatment PIV could be applied to predict the response of pazopanib in STS. Design: We conducted a retrospective analysis of 75 patients who had been treated with pazopanib for recurrent or metastatic non-adipocytic STS. Methods: Our cohort was stratified into either a pre-treatment high PIV group with PIV >= 310 (n = 45) or a low PIV group with PIV <310 (n = 30). We compared their clinical features and outcomes. Cox regression analysis was employed to determine the risk factors of disease progression and mortality. Kaplan-Meier survival curves were utilized to assess both the progression-free survival (PFS) and overall survival (OS). Results: The results revealed that a pre-treatment high PIV (>= 310) is a risk factor for progression under pazopanib (hazard ratio: 1.91; 95% confidence interval: 1.08-3.36; p = 0.025). The median PFS and OS of the pre-treatment high PIV group were found to be significantly lower than the low PIV group (0.33 vs 0.75 years; p = 0.023, 0.46 vs 1.63 years; p = 0.025). Conclusion: High pre-treatment PIV in STS patients may indicate an elevated risk of disease progression and mortality. Pre-treatment PIV reflects inflammation stress and acts as a practical biomarker for STS patients treated with pazopanib.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Prognostic significance of the pretreatment pan-immune-inflammation value in cancer patients: an updated meta-analysis of 30 studies
    Yu, Hai-Jing
    Ren, Yu
    Xia, Jie-Qiong
    FRONTIERS IN NUTRITION, 2023, 10
  • [32] Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
    Rajendra, Rajeev
    Jones, Robin L.
    Pollack, Seth M.
    ONCOTARGETS AND THERAPY, 2013, 6 : 217 - 222
  • [33] Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatment
    Liang, Xuexia
    Bu, Juyuan
    Jiang, Yanhui
    Zhu, Shuqin
    Ye, Qing
    Deng, Yun
    Lu, Wuzhu
    Liu, Qiaodan
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2024, 41 (01)
  • [34] The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy
    Susok, L.
    Said, S.
    Reinert, D.
    Mansour, R.
    Scheel, C. H.
    Becker, J. C.
    Gambichler, T.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (11) : 3103 - 3108
  • [35] Prognostic Potential of the Baseline Pan-Immune-Inflammation Value and Neutrophil/Lymphocyte Ratio in Stage I to III Melanoma Patients
    Gambichler, Thilo
    Stang, Andreas
    Mansour, Rita
    Scheel, Christina H.
    Nick, Celine
    Abu Rached, Nessr
    Becker, Juergen C.
    Susok, Laura
    CANCERS, 2022, 14 (18)
  • [36] Pan-immune-inflammation value is associated with poor prognosis in patients undergoing peritoneal dialysis
    Zhang, Fengping
    Li, Luohua
    Wu, Xianfeng
    Wen, Yueqiang
    Zhan, Xiaojiang
    Peng, Fenfen
    Wang, Xiaoyang
    Zhou, Qian
    Feng, Xiaoran
    RENAL FAILURE, 2023, 45 (01)
  • [37] Prognostic Importance of Inflammatory Indexes in Patients Treated by Pazopanib for Soft Tissue Sarcoma
    Koseci, Tolga
    Haksoyler, Veysel
    Olgun, Polat
    Ata, Serdar
    Nayir, Erdinc
    Duman, Berna B.
    Cil, Timucin
    CLINICAL LABORATORY, 2022, 68 (02) : 340 - 352
  • [38] The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I–III colorectal cancer patients undergoing surgery
    Shun Sato
    Takayuki Shimizu
    Mitsuru Ishizuka
    Kotaro Suda
    Norisuke Shibuya
    Hiroyuki Hachiya
    Yukihiro Iso
    Kazutoshi Takagi
    Taku Aoki
    Keiichi Kubota
    Surgery Today, 2022, 52 : 1160 - 1169
  • [39] Pan-immune-inflammation value is an independent prognostic factor in patients with non-small cell lung cancer with an established nomogram prognostic model
    Wang, Zengming
    Ren, Dahu
    Chen, Shuangqing
    Duan, Guochen
    ASIAN JOURNAL OF SURGERY, 2023, 46 (11) : 4999 - 5000
  • [40] Prognostic Potential of the Baseline Pan-Immune-Inflammation Value and Neutrophil-to-Lymphocyte Ratio in Stage I to III Melanoma Patients
    Reuther, J.
    Mansour, R.
    Scheel, C. H.
    Nick, C.
    Abu Rached, N.
    Becker, J. C.
    Susok, L.
    Gambichler, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 77 - 77